Francisca Córdova

Learn More
BACKGROUND SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SF1126, in patients with advanced solid and B-cell malignancies. PATIENTS AND METHODS SF1126 was administered IV days 1 and(More)
3015 Background: SF1126 is a peptidic prodrug that converts to LY294002, a widely studied dual PI3K/mTOR inhibitor that historically suffered from poor solubility. LY294002 is conjugated to an RGD peptide via a cleavable linker to form SF1126, which demonstrates improved solubility and site selectivity. LY294002 also inhibits other cancer target kinases(More)
Introduction: Activated partial thromboplastin time (aPTT) is one of the most used coagulation tests in preoperative evaluation. Incidental detection of a prolonged aPTT is a problem in primary care, in which the general pediatrician should be able to attend its initial management. Objective: To describe final diagnosis of patients with prolonged aPTT in(More)
  • 1